Qrons Inc. (OTCMKTS:QRON) Stock Sees Buying Activities: What’s the Buzz?
Investors are nowadays almost always on the lookout for innovative biotechnology companies, and one such company that could be worth tracking at this point is Qrons Inc. (OTCMKTS:QRON). The company was in sharp focus yesterday following a key development, and its stock was in action too, as it ended up with gains of as much as 21% amidst heavy interest.
The company is focused on the development of technologies, treatments, and products meant for combating infectious and neuronal diseases, with a special focus on antibiotic-resistant bacteria. Yesterday, Qrons announced it had launched its updated website, titled www.qrons.com. The updates to the website would provide the public at large and investors with a better idea about the strides that the company has made with regard to tackling infectious diseases and sepsis. It would also provide additional information about the efforts of the company in the fight against traumatic brain injuries and other neuronal conditions.
As per a report published by the pedigreed British medical journal The Lancet, antimicrobial resistance led to the deaths of as many as 1.27 million people across the world and was related to a whopping 5 million deaths in 2019. It was further noted in yesterday’s news release that in the United States, the number of antimicrobial-resistant infections stands at more than 2.8 million each year. The Chief Executive Officer of the company, Jonah Meer, spoke about the launch of the website.
He noted that the new website provided further investor relations information that would help people comprehend the range of treatments that were being developed by Qrons to address the various global needs that had remained unaddressed by most firms. He went on to note that the company played a unique role in the world of biotech and welcomed more online engagement with the community as well as its investors.
The company announced on August 14 that it had filed a United States Provisional Patent Application titled Tellurium Compositions and Techniques For Use Therewith. The application in question had been filed on August 9. The filing made by the company was in furtherance of its neuronal and infectious disease treatments. In its news release at the time, it was noted that the patent had been invented by Professor Bengajim Sredini, Professor Michael Albeck, and Dr. Ido Merfeld, the president and co-founder of Qrons.
The two professors belong to Bar Ilan University in Israel. The filing had been made by Qrons after it had signed a License Agreement Term Sheet with the two professors on July 17, 2023, for an exclusive and global license to the intellectual property in tellurium-based compounds that could be used in conjunction with Qrons’ own intellectual property. The patent is related to the therapeutic uses of tellurium-based compounds for the treatment of antibiotic-resistant bacterial infections, traumatic brain injuries, and sepsis. Dr. Merfield, the company’s president, noted that everyone at the company was excited about the filing of the new patent and called it the first step of its research program.
